These findings provide clinical evidence suggesting that monitoring P-gp expression and function in peripheral blood CD56+ cells could provide a non-invasive method to assess chemoresistance in NHL patients and guide personalized treatment [87]. This evidence concerns the gene NCAM1 and non-Hodgkin lymphoma.